Prime Highlights
- A new blood test shows promise in detecting glioblastoma using specific protein markers.
- The test could offer a non-invasive alternative to current methods like MRI scans and surgical biopsies.
Key Facts
- Glioblastoma is one of the most aggressive brain cancers, with a median survival of about 12–15 months after diagnosis.
- Current diagnosis relies on MRI scans and invasive biopsies, making early and repeated detection challenging.
Background
New research has indicated that a few simple blood tests can be used to detect and monitor glioblastoma, one of the most severe brain cancers.
Researchers from the University of Manchester developed a new diagnostic method together with international partners, which uses blood protein markers to detect glioblastoma. The findings have been published in Neuro-oncology Advances, showing evidence on a potential non-invasive technique to explore current diagnostic methods.
Early detection of glioblastoma is thwarted by its nature of rapid growth and complex biology. Patients today must commonly undergo MRI scans or surgical biopsies, which not only involve risk but also are difficult to repeat in many ways.
The new approach relies on detecting two proteins—coagulation factor IX (F9) and cartilage oligomeric matrix protein (COMP)—which together form a “dual-marker” signature. Early testing reported a diagnostic accuracy of over 90%, with correct identification of a patient with glioblastoma, but not in any healthy individuals.
The biomarkers demonstrated their ability to show treatment-related changes, which helped doctors track disease development and treatment effects throughout the entire course of medical research. This would be a major breakthrough of cure situations today, as it remains tough to be sure when treatment is really working.
Experts believe the development will enable healthcare professionals to achieve quicker diagnosis results through less invasive testing methods, which will lead to better patient health results. The test needs more validation through clinical trials before researchers can use it for regular medical testing, which they plan to implement in primary care facilities to identify patients earlier.
